USFDA APPROVAL MOMENTUM CONTINUES

Approval for 3 ANDAs of Cytarabine Injection

December 15, 2011, Bangalore: Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) today announced that it has received approvals from USFDA for **Cytarabine Injection** 20 mg/ mL, packaged in 500 mg/ 25 mL Multiple-dose vials, 20 mg/ mL, packaged in 100 mg/ 5 mL Single-dose vial and 20 mg/ mL, packaged in 1000 mg/ 50 mL Pharmacy Bulk Packages

According to IMS data, the US market for Cytarabine is approximately USD 12.3 Million. Cytarabine is part of the Oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly.

About Cytarabine

Cytarabine is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Cytarabine is used to treat different forms of leukemia, including acute and chronic myelogenous and acute lymphocytic leukemia. It is also used to treat lymphoma, meningeal leukemia and lymphoma (cancers found in the lining of the brain and spinal cord)

About Agila Specialties

Agila Specialties Private Limited is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company’s restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 8 world class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila’s marketing network covers 70 countries and it has partnerships with some of the world’s leading pharmaceutical companies for both developed and emerging markets.
About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company’s website at www.stridesarco.com. For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. V.S. Iyer, CEO - Agila  +91 80 6784 0111</td>
<td>Corporate Voice</td>
</tr>
<tr>
<td>Mr. Ajay Singh : +91 80 6784 0813</td>
<td>Mahesh Nair, +91 9880376648; <a href="mailto:maheshn@corvoshandwick.co.in">maheshn@corvoshandwick.co.in</a></td>
</tr>
<tr>
<td>Mr. Kannan N : +91 98450 54745 (Investors)</td>
<td>Hiba Kunil +91 98807 26372; <a href="mailto:hiba@corvoshandwick.co.in">hiba@corvoshandwick.co.in</a></td>
</tr>
</tbody>
</table>